Actively Recruiting
The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
Led by China-Japan Friendship Hospital · Updated on 2025-02-27
500
Participants Needed
2
Research Sites
53 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Definitive radiotherapy is one of the important methods for inoperable locally advanced lung cancer. The recommended dose for definitive radiotherapy is 60-70Gy, and the optimal dose is still uncertain. Residual lesion after radiotherapy is a risk factor for recurrence. High doses to targeted tumor areas can effectively improve the local control rate, while minimizing toxic side effects. The regression pattern of primary lesions in lung caner after radiotherapy has not been clarified. This study intends to retrospectively collect clinical data of lung cancer patients with definitive radiotherapy, and explore the pattern of tumor regression after radiotherapy. It will help optimize the radiotherapy plan for lung cancer, so as to improve the efficacy and prognosis.
CONDITIONS
Official Title
The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with stage II-III lung cancer confirmed by pathology or medical record
- No surgery before radiotherapy
- Received definitive radiotherapy to primary lung lesion with conventional fractionation dose 650Gy or stereotactic radiotherapy with biologically effective dose 63100Gy
- Target lung lesion measurable on imaging
- Imaging data available both before and after radiotherapy
- Completed the planned radiotherapy or received the defined definitive dose
You will not qualify if you...
- Primary lung lesion treated with surgery or ablative therapy before radiotherapy
- Radiotherapy plan not completed or actual dose received less than definitive dose (conventional fractionation dose <50Gy or biologically effective dose <100Gy)
- Required imaging data unavailable
- Other conditions considered unsuitable for enrollment by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
2
Renmin Hospital of Wuhan University
Wuhan, Hubei, China, 430060
Actively Recruiting
Research Team
G
Guangying Zhu, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here